Search Result

Pathways Recommended:	Anti-infection

Results for "

RSV infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	RSV (23) Biochemical Assay Reagents (1) IGF-1R (1) Influenza Virus (2) NF-κB (1)
By Research Areas:	Cancer (2) Infection (22) Inflammation/Immunology (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Targets Recommended: RSV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99586

Suptavumab REGN2222	RSV	Infection
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on *RSV* A and B subtypes. Suptavumab can be used for the research of RSV infection .

HY-P99756

Nirsevimab MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .

HY-P9944

Palivizumab 1 Publications Verification MEDI 493	RSV	Infection Inflammation/Immunology Cancer
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a K_d value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .

HY-163773

JNJ-7950	RSV	Infection
JNJ-7950 (compound 5c) exhibits antiviral activity against *RSV* with an EC₅₀ value of 0.78 nM. JNJ-7950 can be used in the study of respiratory tract infections .

HY-123475A

Sisunatovir hydrochloride 3 Publications Verification RV521 hydrochloride	RSV	Infection
Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC₅₀ values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice .

HY-123475

Sisunatovir 3 Publications Verification RV521	RSV	Infection
Sisunatovir (RV521) is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC₅₀ values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir inhibits RSV infection and reduces virus titers in the lungs of mice .

HY-130627

RSV/IAV-IN-2	RSV Influenza Virus	Infection
RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .

HY-130626

RSV/IAV-IN-1	RSV Influenza Virus	Infection
RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .

HY-163567

RSV-IN-10	RSV	Infection
RSV-IN-10 (compound 6a) shows antiviral activity against RSV with the IC₅₀ of 4 μM. RSV-IN-10 can be used for study of respiratory infection .

HY-163568

RSV-IN-11	RSV	Infection
RSV-IN-11 (compound 10b) shows antiviral activity against RSV with the IC₅₀ of 6.32 μM. RSV-IN-10 can be used for study of respiratory infection .

HY-171983

RSV-IN-13	RSV	Infection
RSV-IN-13 (compound 24) is a selective *RSV* fusion protein inhibitor with antiviral activity. RSV-IN-13 has an EC₅₀ of 444.2 nM against RSV A2 strain and a CC₉₀ of 23.7 μM in HepG2 cells. RSV-IN-13 can block the virus from entering host cells. RSV-IN-13 can be used to study RSV infection .

HY-109004

Enzaplatovir BTA-C585	RSV	Infection
Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection .

HY-154968

RSV L-protein-IN-5	RSV	Infection
RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC₅₀=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-115574

RSV L-protein-IN-1	RSV	Infection
RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC₅₀=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-168616

CL-A3-7	RSV IGF-1R	Infection
CL-A3-7 is a virus-cell fusion inhibitor targeting the *RSV* F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type *RSV* and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research .

HY-114721

BTA-9881 MEDI-564	RSV	Infection
BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC₅₀: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property .

HY-109004A

(S)-Enzaplatovir (S)-BTA-C585	RSV	Cancer
(S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC₅₀ of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77) .

HY-P99209

Motavizumab MEDI-524	RSV	Infection
Motavizumab (MEDI-524) is an anti-human *RSV* (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .

HY-P991494

IN-002	RSV	Infection
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.

HY-P991499

EVO-46120	RSV	Infection
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.

HY-138956

MAY0132	NF-κB RSV	Infection
MAY0132 is a potent and selective EPAC2 inhibitor with an IC₅₀ of 0.4 μM. MAY0132 significantly inhibits replication of HMPV, AdV and *RSV, reduces viral infection-induced cytokine/chemokine production, and inhibits NF-κB* activation. MAY0132 has antiviral activity and can be used in the study of respiratory virus infection .

HY-W251428

Phosphatidylglycerols (egg) sodium salt Egg PG	Biochemical Assay Reagents	Others
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .

HY-P991495

VIR-8190	RSV	Infection
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-161877

GS-7682	RSV	Infection
GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease .

Cat. No.	Product Name	Type

HY-W251428

Phosphatidylglycerols (egg) sodium salt Egg PG	Drug Delivery
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .

Phosphatidylglycerols (egg) sodium salt

Egg PG

Drug Delivery

Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .

Cat. No.	Product Name	Target	Research Area